

THE LAW OFFICE OF STEPHEN JOSEPH LASKERO A California Law office 3451 Via Montebello, Suite 192-409 Carlsbad, CA 92009 <u>stephenlaw7@ymail.com</u> 760-452-6778

OTC Markets Group Inc. 300 Vesey Street, 12th Floor, New York, NY 10282, issuers@otcmarkets.com

April 24, 2024

Re: Attorney Letter for National Asset Recovery Corp. (REPO) Regarding the Availability of Current Public Information

Dear Sir or Madam:

The purpose of this correspondence is to inform OTC Markets and the public regarding the availability of current public information for the "issuer" National Asset Recovery Corp. (REPO), a Nevada Corporation. The undersigned has been retained as counsel for the issuer for the purpose of authoring an opinion regarding the availability of current public information as that term is defined in Rule 144(c) (2) of the Securities Act of 1933. The OTC Markets Group is entitled to rely on this opinion and may publish this letter through the OTC Market Disclosure and News Service (otcmarkets.com) for the purpose of making this information available to the public.

The undersigned and sole author of this correspondence is licensed to practice law in the state of California, and the United States District Court for the Southern District of California. The undersigned is also a United States resident and is entitled to practice before the United States Securities and Exchange Commission (the "SEC") and has not been disciplined or otherwise prohibited from that practice. The undersigned is not currently and never has been subject to an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission, the Financial Industry Regulatory Authority, or any other federal, state, or foreign entity. Moreover, the undersigned never has been and is not currently suspended or barred from practice in any foreign or domestic court of law or other tribunal or been charged in a civil or criminal case. Finally, the undersigned does not own any stock in National Asset Recovery Corporation.

Limitations, Assumptions and Facts

In support of this opinion, the undersigned has reviewed applicable federal laws, rules and regulations including specifically the Securities Act of 1933, and other relevant laws deemed necessary to render this opinion. The undersigned has also reviewed the corporate records determined to be appropriate for this

opinion, verified or assumed the legal capacity of all persons and entities, the genuineness of all signatures, the authenticity of all documents, and the veracity of all individuals who provided information regarding this matter.

In the portion of this letter that relies upon the information and documentation contained in the OTC disclosures of the issuer, the undersigned has not made, nor will he make any independent investigation regarding the representations contained therein. However, during my review of the documentation and conversations with the issuer's representatives, I did not reach the conclusion that any of the information I received was incorrect or disingenuous. Therefore, the information relied upon is believed to be true and reliable, and the documents genuine. This opinion is based solely on the facts, limitations and assumptions described in this letter and is not intended to be expanded to any other situation not discussed herein.

In the formation of the opinions contained in this letter, the undersigned has examined the following specific documents available by publication through the OTC Disclosure and News service:

Publish Date	Title	End Date
04/01/2024	Annual Report- Annual Report	12/31/2023
01/05/2024	Supplemental Information – Current Report	01/05/2023
12/04/2023	Quarterly report – Amended Quarterly Report	09/30/2023
11/20/2023	Quarterly report - Quarterly Report ended Sept. 30, 2023	09/30/2023
11/13/2023	Notification of Late filing – Extension	09/30/2023
08/21/2023	Quarterly Report- Quarterly Report ended June 30, 2023	06/30/2023
08/14/2023	Notification of Late Filing	06/30/2023
06/16/2023	Supplemental Information-Disclosure Statement Regarding Definitive Merger Agreement	06/15/2023
06/12/2013	Officer/Director Disclosure-Current Report	06/12/2023
06/12/2023	Supplemental Information – Merger Agreement	06/12/2023
04/05/2023	Annual Report – REPO Annual Report Amended	12/31/2022
03/31/2023	Annual Report- REPO Annual Report Amended	12/31/2022
03/29/2023	Annual Report- REPO Annual Report Amended	12/31/2022
03/28/2023	Supplemental Information- Current Report MOU	12/31/2022
11/10/2022	Quarterly Report-REPO Quarterly Report	09/30/2022
08/08/2022	Quarterly Report - REPO Quarterly Report	06/30/2022

05/11/2022	Quarterly Report – REPO Quarterly Report	03/31/2022
03/21/2022	Atty. Letter with Respect to Current Information	12/31/2021

The undersigned also reviewed the Pink Basic Disclosure Guidelines for the fiscal year ending December 31, 2023, and the new guidance for Submitting attorney letters dated January 5, 2023.

The undersigned has met with the issuer's current Chief Executive Officer, Vishal Patel, via telephone conference on at least three separate occasions, in February, March and April of 2024. During these conversations, the information published by the issuer was discussed and confirmed. The undersigned has also reviewed the financial information contained in the above referenced OTC disclosures and believes it to be true and accurate to the best of his knowledge. If any of the disclosed information upon which this opinion is based is untrue or substantially inaccurate, this opinion is withdrawn.

The financial statements contained in the information for the fiscal year ending December 31, 2022, are unaudited financial statements prepared by Ken Kerster. Mr. Kerster has over 30 years of accounting experience and has prepared the financial statements for the Issuer for the past several years. The undersigned is informed and believes that the relevant information has been prepared in conformance with all recognized professional standards including all GAAP requirements. The undersigned is informed and believes that the company.

The financial statements contained in the information for the fiscal year ending December 31, 2023, are unaudited financial statements prepared by Rachael Boulds, a certified public accountant licensed in the state of Utah. Ms. Boulds has over 30 years of accounting experience preparing financial statements for mandatory and voluntary reporting companies. The undersigned is informed and believes that the relevant information has been prepared in conformance with all recognized professional standards including all GAAP requirements. Other than being an independent service provider, Ms. Boulds has no other affiliation with the issuer.

After discussing this matter with the CEO of the issuer, the undersigned has received confirmation that none of the individuals identified as owning 5% or more of the company's common stock are currently under investigation by any federal or state agency for the violation of any securities laws, and never have been charged, indited or been found guilty of any securities law violations including legal counsel. Consequently, to the best of my knowledge, after reasonable inquiry, the above referenced information can be relied upon by OTC Markets as being true.

The undersigned confirmed the number of outstanding shares of the issuer by reviewing the information contained in the yearend financial statement for 2023, contacting the transfer agent, Manhattan Transfer Registrar Co., and reviewing the REPO "Security Details" available on the OTC Disclosure and News Service.

The transfer agent is registered with the Securities and Exchange Commission and has verified the information contained on the issuer's latest disclosure statement for the relevant period to the best of the undersigned's knowledge.

Non-Shell Status

According to the issuer's OTC disclosures, it is no longer a "shell company" as defined by Rule 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934. My factual inquiries support this conclusion and are based upon its OTC disclosures and my discussions with management.

Legal Opinion

It is the undersigns opinion that the information provided by the issuer presents "adequate current public information" regarding the issuer and its securities. This information is published on the OTC Disclosure & News Service and is available to the public as defined in Rule 144(c)(2) of the Securities Act of 1933. The available information contains all of the information a broker-dealer would need to publish a quote for the Securities under Rule 15c2-11 of the Securities Exchange Act of 1934.

The opinions contained in this letter are limited to the securities laws of the United States as well as the facts and circumstances described herein. Nothing in this correspondence should be construed as a guarantee or a definitive opinion of fact. All opinions assume the documents and statements of management are genuine, and the facts communicated in support of this opinion are true. This letter is being presented in accordance with the guidelines of the OTC Market Disclosure and New Service and OTC is hereby granted permission and the rights to publish this letter. This correspondence applies only to the law, facts and circumstances described herein and should not be relied upon by any other person or entity for any purpose. No other publication, use or reproduction of this correspondence is authorized without the specific written permission of the undersigned.

Regards,

Stephen Jaskero

Stephen Laskero Attorney at Law